FindTrial
Sign In

Exploring Prognostic Factors for Heavy Ion Therapy of Bone and Soft Tissue Sarcomas

Exploring prognostic factors and high-LET treatment-specific responses in high-LET heavy ion radiotherapy for bone and soft tissue sarcomas. - Research on Heavy Ion Beam Therapy for Bone and Soft Tissue Sarcoma

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000055681
Enrollment
150
Registered
2024-10-01
Start date
2024-09-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and Soft Tissue Sarcoma

Interventions

None listed

Sponsors

National Institutes for Quantum Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Adult patients (18 years of age or older) scheduled for heavy ion radiotherapy for bone and soft tissue sarcoma at QST Hospital. (Any treatment before or after the heavy ion radiotherapy is acceptable.) 2) Patients who have been fully informed about their participation in this study, fully understand the study, and have given appropriate written consent of their own free will.

Exclusion criteria

Exclusion criteria: Patients who are judged by the investigator or other physicians to be inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Analysis of blood components using blood samples taken before the start of treatment, on the 11th day of treatment, and after the end of treatment on the last day of treatment. Whenever possible, the same analysis will be done during follow-up visits within 5 years of the end of treatment.—

Countries

Japan

Contacts

Public ContactReiko Imai

National Institutes for Quantum Science and Technology QST Hospital, Radiation Oncology Promotion Section

imai.reiko@qst.go.jp043-206-3306

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026